Eli Lilly lifts revenue forecast on bumper obesity drug sales

Increased manufacturing capacity for Eli Lilly's highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by US$3-billion on Aug. 8 - and its shares jumped 13 per cent.

Reuters